PremalDilipLullaMD

Hematologic Oncology

Physician

Dr. Lulla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1 Baylor Plz
Dept. Of Internal Medicine
Houston, TX 77030
Phone+1 713-798-0190

Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2012 - 2015
Baylor College of MedicineResidency, Internal Medicine, 2009 - 2012
Dr. DY Patil Medical CollegeClass of 2008

Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine Start of enrollment: 2021 Aug 06
Active, not recruiting
Phase 1
Anti-SARS Cov-2 T Cell Infusions for COVID 19 Start of enrollment: 2020 Nov 04
Terminated
Phase 1
STRIDE Biorepository Start of enrollment: 2017 Mar 13
Recruiting
Roles: Contact
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) Start of enrollment: 2016 Feb 01
Recruiting
Phase 1
Roles: Principal Investigator, Contact
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Roles: Contact
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma Start of enrollment: 2015 Apr 01
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas Start of enrollment: 2024 Mar 01
Withdrawn
Phase 1
Roles: Contact, Principal Investigator
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

PubMed

Approved CAR-T therapies have reproducible efficacy and safety in clinical practice.
Daniel Goyco Vera, Hiral Waghela, Mohamed Nuh, Jonathan Pan, Premal Lulla
Human Vaccines & Immunotherapeutics. 2024-12-31
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.
Ibrahim N Muhsen, Kristen E Shaver, Tao Wang, Mengfen Wu, Premal Lulla
Transplantation and Cellular Therapy. 2024-12-01
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.
David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney
Nature. 2024-11-27

Baylor Awarded CPRIT Grants for Cancer Research and Prevention ProgramsAugust 20th, 2020
An Early Look at When CAR-T Therapy Fails Patients with CLLMarch 10th, 2020